Please wait while the transcript is being prepared...
0:00
Hello, my name is Scott Kahan.
I'm an Obesity Physician
from the United States,
Johns Hopkins Bloomberg
School of Public Health.
And I'll be speaking today
about "Obesity Pharmacotherapy".
I'll describe options
that we have available
and some of their uses
in clinical practice to treat obesity.
Before we get there, let's just start
with a little bit of a broad description
about obesity.
0:27
So here's an example,
showing the extreme growth
in obesity prevalence
over the course of the past few decades
in the United States.
So as you can see, in 1985,
prevalence in all states
was either quite low
or we didn't have data.
So all of those states
that have no color,
that actually suggests
that there's no surveillance system
in place.
So just three decades ago,
many states didn't even count
the issue with obesity.
They weren't counting the data.
They didn't have
a surveillance system in place
because they didn't think
it was an important enough problem.
The states that were counting,
there were relatively low prevalences.
On the other hand,
when we go ahead just three decades,
it's of course a very different story.
On the one hand,
there are no more states in white.
Everybody is keeping track.
Every state as well as every country
worldwide is now keeping track.
It's a big public health problem.
Moreover, we don't see
any of those same colors from 1985
because there are no states
that have as low a prevalence,
as there was in 1985.
Now we have additional colors
denoting much higher
prevalences of obesity.
Nationally, in the United States,
there's about a 35%
prevalence of obesity.
And that is defined
as a BMI greater than 30.
And in many states
the prevalence is quite higher.
